Mesoblast Limited (MESO)
NASDAQ: MESO · Real-Time Price · USD
15.19
+0.34 (2.29%)
At close: Aug 13, 2025, 4:00 PM
16.00
+0.81 (5.33%)
Pre-market: Aug 14, 2025, 9:00 AM EDT
Mesoblast Employees
Mesoblast had 73 employees as of June 30, 2024. The number of employees decreased by 10 or -12.05% compared to the previous year.
Employees
73
Change (1Y)
-10
Growth (1Y)
-12.05%
Revenue / Employee
$77,671
Profits / Employee
-$1,415,767
Market Cap
2.04B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
MESO News
- 27 days ago - Successful Commercial Launch of Ryoncil® - GlobeNewsWire
- 6 weeks ago - Mesoblast Targets Accelerated FDA Approval For Heart Failure Drug Revascor - Benzinga
- 6 weeks ago - Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure - GlobeNewsWire
- 2 months ago - Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD - GlobeNewsWire
- 3 months ago - FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil® - GlobeNewsWire
- 3 months ago - Bullish On Mesoblast: Shifting To Commercial Stage With Ryoncil Approval And Revascor Trials - Seeking Alpha
- 3 months ago - Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025 - GlobeNewsWire
- 3 months ago - Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board - GlobeNewsWire